ResMed saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 66 to 75.
Can You Really Time The Stock Market?
IBD's unique rating tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners often have an 80 or higher RS Rating as they begin their largest runs. See if ResMed can continue to rebound and clear that threshold.
ResMed is trying to complete a cup without handle with a 263.05 buy point. See if it can clear the breakout price in heavy trade.
ResMed showed 11% EPS growth last quarter. Sales rose 8%.
ResMed earns the No. 7 rank among its peers in the Medical-Products industry group. Penumbra, Boston Scientific and Axogen are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
